NIH COVID-19 Treatment Guidelines Panel Invites Top Ivermectin Researchers to Discuss the Evidence of Efficacy to Date

NIH COVID-19 Treatment Guidelines Panel Invites Top Ivermectin Researchers to Discuss the Evidence of Efficacy to Date

Just on Wednesday, the National Institutes of Health (NIH) invited the Front Line COVID-19 Critical Care Alliance (FLCCC) to present to this apex national research agency’s COVID-19 Treatment Guidelines Panel. The most influential of any such group worldwide, the NIH’s Treatment Guidelines Panel now is taking the time to review the unfolding ivermectin situation. A key question: does the accumulation of data to date in connection with ivermectin COVID-19 randomized controlled trials indicate sufficient evidence for institute action? TrialSite commends the NIH for now reviewing this important and unfolding situation. Of course, such a meeting wouldn’t be possible if it were not for the dedicated, committed and relentless efforts of the physician/researchers' embrace of an unfolding story TrialSite had been chronicling since April. The FLCCC, led by Dr. Pierre Kory and Dr. Paul Marik, along with prominent British researcher, Dr. Andrew Hill, affiliated with the University of Liverpool in the UK, presented their respective meta-analysis findings to date. The NIH's powerful Panel indicated their Guidelines should be updated by February. 

TrialSite works closely ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee